The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
Open accessAbstract
Background: Immunosenescence, the age-related decline of immunity, affects the immune responses of melanoma patients. Through immune responses, immune checkpoint inhibitors (ICIs) exert their antitumor robustness. In different ages of melanoma patients, especially the older patients, the effectiveness of ICIs remains unclear. It is still controversial whether ICIs should be used in treating older patients. Materials and methods: The authors included clinical trials of ICIs in older and younger patients. The authors used hazard ratio (HR) and 95% CI of overall survival (OS). Results: From four phase III randomized clinical trials 2,251 melanoma patients were included. We found that ICIs significantly prolonged the OS for melanoma patients in both younger (HR, 0.71; 95% CI, 0.60–0.82; P <0.001) and older groups (HR, 0.62; 95% CI, 0.41–0.83; P <0.001) compared with controls. Anti-programmed death-1 (PD-1) agents appeared to be more efficient in older melanoma patients (HR, 0.34; 95% CI, 0.14–0.53) versus younger patients (HR, 0.52; 95% CI, 0.26–0.78). Conclusion: ICIs significantly prolonged the OS for melanoma patients in both younger and older groups than controls. Anti-PD-1 agents were more efficient in older melanoma patients versus younger patients. ICIs could be used for older melanoma patients. Keywords: immunosenescence, aging, immune checkpoint inhibitor, PD-1, melanoma
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anti-PD-1 drugs are effective for both young and elderly patients.
“A meta-analysis of randomized trials showed that although anti-PD-1 drugs are effective for both young and elderly patients, the risk of death among elderly patients is comparable or improved compared to that of patients subjected to control interventions, with no increased toxicity [155–158].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [156]
Anti-PD-1 drugs cause no increased toxicity in elderly patients.
“with no increased toxicity [155–158].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [156]
The risk of death among elderly patients receiving anti-PD-1 drugs is comparable or improved compared to control interventions.
“the risk of death among elderly patients is comparable or improved compared to that of patients subjected to control interventions, with no increased toxicity [155–158].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [156]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,580 · see citing works
Ribas, A., Kefford, R. F., Marshall, M. A., Punt, C. J. A., Haanen, J. B. A. G., Mármol, M., Garbe, C., Gogas, H. J., Schachter, J., Linette, G. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6112 · Cited by 802 · see citing works
Age and immunity: What is “immunosenescence”?
Pawelec, G. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2017.10.024 · Cited by 606 · see citing works
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., et al. (2015) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 495 · see citing works
T cell subset-specific susceptibility to aging
Czesnikiewicz-Guzik, M., Lee, W.-W., Cui, D., Hiruma, Y., Lamar, D. L., Yang, Z.-Z., Ouslander, J. G., Weyand, C. M., & Goronzy, J. J. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.12.002 · Cited by 478 · see citing works
Immunosenescence in aging: Between immune cells depletion and cytokines up-regulation
Ventura, M. T., Casciaro, M., Gangemi, S., & Buquicchio, R. (2017) · Clinical and Molecular Allergy · doi:10.1186/s12948-017-0077-0 · Cited by 389 · see citing works
Nishijima, T. F., Muss, H. B., Shachar, S. S., & Moschos, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.006 · Cited by 293 · see citing works
Immune checkpoint inhibitors and elderly people: A review
Daste, A., Domblides, C., Gross‐Goupil, M., Chakiba, C., Quivy, A., Cochin, V., de Monès, E., Larmonier, N., Soubeyran, P., & Ravaud, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.044 · Cited by 189 · see citing works
Ferrara, R., Mezquita, L., Auclin, E., Chaput, N., & Besse, B. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.003 · Cited by 163 · see citing works
Impaired Dendritic Cell Function in Aging Leads to Defective Antitumor Immunity
Grolleau‐Julius, A., Harning, E. K., Close, L. A., & Yung, R. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5769 · Cited by 151 · see citing works
Immunotherapy comes of age: Immune aging & checkpoint inhibitors
Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.02.001 · Cited by 133 · see citing works
Plowden, J., Renshaw-Hoelscher, M., Gangappa, S., Engleman, C., Katz, J. M., & Sambhara, S. (2004) · Cellular Immunology · doi:10.1016/j.cellimm.2004.07.001 · Cited by 98 · see citing works
da Silva, I. P., & Long, G. V. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000405 · Cited by 74 · see citing works
Bolton, C., & Smith, P. A. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.10.005 · Cited by 57 · see citing works
Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
Keating, G. M. (2016) · Drugs · doi:10.1007/s40265-016-0589-9 · Cited by 45 · see citing works
Wu, Y. C., Shi, H. M., Jiang, M., Qiu, M., Jia, K., Cao, T., Shang, Y., Shi, L., Jiang, K., & Wu, H. (2017) · International Journal of Cancer · doi:10.1002/ijc.31012 · Cited by 42 · see citing works
Guo, Z., Tilburgs, T., Wong, B., & Strominger, J. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1414780111 · Cited by 40 · see citing works
Wu, Y. C., Ju, Q., Qian, B., Zhang, F., & Shi, H. M. (2017) · Oncotarget · doi:10.18632/oncotarget.23678 · Cited by 29 · see citing works
Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0492-9 · Cited by 27 · see citing works
The safety of nivolumab for the treatment of metastatic melanoma
O’Reilly, A., & Larkin, J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351537 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Immunosenescence: a key player in cancer development
Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510 · see citing works
Impact of Age-, Cancer- and Treatment-Driven Inflammation on T Cell Function and Immunotherapy
Quinn, K. M., Kartikasari, A. E. R., Cooke, R. E., Koldej, R. M., Ritchie, D. S., & Plebanski, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0520-466r · Cited by 31 · see citing works
- Authors
- Li, P., Yang, X., Feng, Y., Wu, L., Ma, W., Ding, G., Wei, Y., & Sun, L.
- Affiliations
- Nanjing Medical University (CN)
- Suzhou Municipal Hospital (CN)
- Corresponding author
- Sun, Lan
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-10
- Volume
- Volume 11
- Pages
- 7521-7527
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC6208870
- OpenAlex
- W2898256009
- Cited by
- 29
- References
- 25
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2 · 2023: 6 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 1
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immunosenescence, immune checkpoint inhibitors, melanoma, elderly patients, anti-PD-1 therapy, overall survival, age-related immune decline, immunotherapy efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
